

SEQUENCE LISTING

<110> Shionogi & Co., Ltd

<120> Composition for promoting passive extension of bladder smooth muscle

<130> S0042PCT

<140>

<141>

<150> JP P1999-177549

<151> 1999-06-23

<160> 6

<170> PatentIn Ver. 2.0

<210> 1

<211> 1457

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (165)..(719)

<220>

<221> mat peptide

<222> (447)..(602)

<400> 1

ggcacgagct ggatagaaca gctcaagcct tgccacttcg ggctttctac tgcagctggg 60

cttggacttc ggagttttgc cattgccagt gggacgtctg agactttctc ctccaagtac 120

ttggcagatc actctcttag cagggctctg gcttcgcagc cggg atg aag ctg gtt 176

Met Lys Leu Val

10/018924-1304

[illegible]

$\frac{[P]}{[M]}$, $\frac{[P]}{[M]}$, $\frac{[P]}{[M]}$, $\frac{[P]}{[M]}$, $\frac{[P]}{[M]}$

[illegible][illegible][illegible]

$\frac{m_1}{m_2}$	$\frac{m_1}{m_2}$	$\frac{m_1}{m_2}$	$\frac{m_1}{m_2}$	$\frac{m_1}{m_2}$	$\frac{m_1}{m_2}$
ratio	ratio	ratio	ratio	ratio	ratio

[illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible]

$\frac{m}{n}$, $\frac{p}{q}$, $\frac{r}{s}$, $\frac{t}{u}$, $\frac{v}{w}$, $\frac{x}{y}$, $\frac{z}{a}$

Arg Thr Leu Val Ser Ser Lys Pro Gln Ala His Gly Ala Pro Ala Pro

70

75

80

Pro Ser Gly Ser Ala Pro His Phe Leu

85

90

<210> 3

<211> 1493

<212> DNA

<213> Sus scrofa

<220>

<221> CDS

<222> (148)..(711)

<220>

<221> mat peptide

<222> (430)..(585)

<400> 3

gcggaacagc tcgagccctg ccacctctag tttcttacca cagcttggac gtcgggggtt 60

tgccactgcc agagggacgt ctacagacttc atcttcccaa atcttggcag atcaccacct 120

tagcagggtc tgcacatctc agccggg atg aag ctg gtt ccc gta gcc ctc atg 174

Met Lys Leu Val Pro Val Ala Leu Met

-90

tac ctg ggc tgc ctc gcc ttc ctg ggc gct gac aca gct cgg ctc gac 222

Tyr Leu Gly Ser Leu Ala Phe Leu Gly Ala Asp Thr Ala Arg Leu Asp

-85

-80

-75

-70

gig gcg gca gag ttc cga aag aaa tgg aat aag tgg gct cta agt cgt 270

Val Ala Ala Glu Phe Arg Lys Lys Trp Asn Lys Trp Ala Leu Ser Arg

100199412901

[illegible]

-90 -85 -80

-75 -70 -65

-60 -55 -50

-45 -40 -35

-30 -25 -20 -15

-10 -5 -1 1

5 10 15

20 **25** **30**

35 40 45 50

55

70 . . . 75 80

Pro Ala His Gln Val Leu Ala Thr Leu Phe Arg Ile

<220>
 <221> CDS
 <222> (154).. (708)

<400> 5
tccagccitt accgctcctg gtttctcggc ttctcaicgc agtcagtcit ggactittgcg 60
ggttttgccg ctgtcagaag gacgtctcgg actttctgct tcaagtgcit gacaactcac 120
cctttcagca gggatatcga gcatcgctac aga atg aag ctg gtt tcc atc gcc 174
Met Lys Leu Val Ser Ile Ala
-90

ctg atg tta ttg ggt tcg ctc gcc gtt ctc ggc gcg gac acc gca cgg 222
Leu Met Leu Leu Gly Ser Leu Ala Val Leu Gly Ala Asp Thr Ala Arg
-85 -80 -75

ctc gac act tcc tcg cag ttc cga aag aag tgg aat aag tgg gcg cta 270
Leu Asp Thr Ser Ser Gln Phe Arg Lys Lys Trp Asn Lys Trp Ala Leu
-70 -65 -60 -55

agt cgt ggg aag agg gaa cta caa gcg tcc agc agc tac cct acg ggg 318
Ser Arg Gly Lys Arg Glu Leu Gln Ala Ser Ser Ser Tyr Pro Thr Gly
-50 -45 -40

-60

-55

-50

Ser Ser Ser Tyr Pro Thr Gly Leu Val Asp Glu Lys Thr Val Pro Thr

-45

-40

-35

-30

Gln Thr Leu Gly Leu Gln Asp Lys Gln Ser Thr Ser Ser Thr Pro Gln

-25

-20

-15

Ala Ser Thr Gln Ser Thr Ala His Ile Arg Val Lys Arg Tyr Arg Gln

-10

-5

-1 1

Ser Met Asn Gln Gly Ser Arg Ser Thr Gly Cys Arg Phe Gly Thr Cys

5

10

15

Thr Met Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr Asp Lys Asp

20

25

30

35

Lys Asp Gly Met Ala Pro Arg Asn Lys Ile Ser Pro Gln Gly Tyr Gly

40

45

50

Arg Arg Arg Arg Arg Ser Leu Pro Glu Val Leu Arg Ala Arg Thr Val

55

60

65

Glu Ser Ser Gln Glu Gln Thr His Ser Ala Pro Ala Ser Pro Ala His

70

75

80

Gln Asp Ile Ser Arg Val Ser Arg Leu

85

90

1004004 1004004 1004004